AI-Digital-Physical Convergence: The Future Of DMTA In Drug Discovery & Development

Drug discovery and development are increasingly constrained by fragmented workflows, manual data handoffs, and slow feedback between experimental stages. A digitally connected, AI‑enabled DMTA (design–make–test–analyze) framework offers a path forward by unifying physical experimentation with machine‑readable data, automation, and predictive models. By replacing manual translation steps with structured data, digital twins, and closed‑loop learning, teams can reduce error, improve productivity, and accelerate confident decision‑making. This convergence of AI, digital infrastructure, and laboratory execution reshapes how compounds are designed, synthesized, tested, and optimized—from early discovery through CMC and process lifecycle management.

Access the full white paper to explore how virtuous DMTA cycles enable faster lead optimization, more reliable scale‑up, and data integrity that supports both innovation and regulatory readiness.